KIRITSY CHRISTOPHER P 4
4 · PALVELLA THERAPEUTICS, INC. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Palvella (PVLA) Director Christopher Kiritsy Receives 3,000-Share Award
What Happened
Christopher P. Kiritsy, a director of Palvella Therapeutics, was granted a derivative equity award on 2026-06-10 covering 3,000 shares. The filing reports a $0.00 per-share acquisition price (award/derivative) — total reported cash consideration $0. This is an equity grant (award), not a purchase or sale of stock.
Key Details
- Transaction date: 2026-06-10; filing date: 2026-06-12.
- Transaction type: Award/derivative (Form 4 code "A"); 3,000 shares granted at $0.00.
- Shares owned after transaction: not disclosed in the filing.
- Footnote: The award vests on the earlier of (i) the first anniversary of the grant date or (ii) the issuer's next annual meeting, subject to continued service.
- No indication in the filing that shares were sold or immediately exercised; this was a time‑based equity grant.
Context
This is a standard director equity award intended for compensation/retention. Derivative awards with $0.00 listed typically represent stock options, restricted stock units, or similar grants rather than an open‑market purchase or sale. Such grants do not by themselves signal buying or selling intent — they reflect compensation and vesting tied to continued board service.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-10+3,000→ 3,000 totalExercise: $102.19Exp: 2036-06-10→ Common Stock (3,000 underlying)
Footnotes (1)
- [F1]The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.